These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33634982)

  • 1. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.
    Zhang X; Hu B; Sun YF; Huang XW; Cheng JW; Huang A; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J; Yang XR
    Clin Transl Med; 2021 Feb; 11(2):e335. PubMed ID: 33634982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZnAs@SiO
    Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
    Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
    [No Abstract]   [Full Text] [Related]  

  • 3. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.
    Wang HY; Zhang B; Zhou JN; Wang DX; Xu YC; Zeng Q; Jia YL; Xi JF; Nan X; He LJ; Yue W; Pei XT
    Cell Death Dis; 2019 Jun; 10(6):453. PubMed ID: 31186405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.
    Zhang KZ; Zhang QB; Zhang QB; Sun HC; Ao JY; Chai ZT; Zhu XD; Lu L; Zhang YY; Bu Y; Kong LQ; Tang ZY
    J Hematol Oncol; 2014 Mar; 7():28. PubMed ID: 24678763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop.
    Qiu Y; Dai Y; Zhang C; Yang Y; Jin M; Shan W; Shen J; Lu M; Tang Z; Ju L; Wang Y; Jiao R; Xia Y; Huang G; Yang L; Li Y; Zhang J; Wong VKW; Jiang Z
    J Exp Clin Cancer Res; 2018 Dec; 37(1):321. PubMed ID: 30572915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
    Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-methylation of miR-148a by arsenic trioxide enhances sensitivity to chemotherapy via inhibiting the NF-κB pathway and CSC like properties.
    Wang Y; Jiang F; Jiao K; Ju L; Liu Q; Li Y; Miao L; Li Z
    Exp Cell Res; 2020 Jan; 386(2):111739. PubMed ID: 31759055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.
    Yamashita T; Honda M; Nio K; Nakamoto Y; Yamashita T; Takamura H; Tani T; Zen Y; Kaneko S
    Cancer Res; 2010 Jun; 70(11):4687-97. PubMed ID: 20484035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
    Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
    Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
    Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW
    Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
    Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
    Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
    Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
    Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma.
    Zhang F; Duan J; Song H; Yang L; Zhou M; Wang X
    Drug Dev Res; 2021 May; 82(3):430-439. PubMed ID: 33244794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
    Rangwala F; Williams KP; Smith GR; Thomas Z; Allensworth JL; Lyerly HK; Diehl AM; Morse MA; Devi GR
    BMC Cancer; 2012 Sep; 12():402. PubMed ID: 22963400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
    Zhang Y; Guan DX; Shi J; Gao H; Li JJ; Zhao JS; Qiu L; Liu J; Li N; Guo WX; Xue J; Zhou FG; Wu MC; Wang HY; Xie D; Cheng SQ
    J Hepatol; 2013 Dec; 59(6):1255-63. PubMed ID: 23867314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma.
    Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K
    ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo.
    Shen L; Zhang G; Lou Z; Xu G; Zhang G
    BMC Complement Altern Med; 2017 Feb; 17(1):106. PubMed ID: 28187727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.
    Wang H; Hou W; Perera A; Bettler C; Beach JR; Ding X; Li J; Denning MF; Dhanarajan A; Cotler SJ; Joyce C; Yin J; Ahmed F; Roberts LR; Qiu W
    Cell Rep; 2021 Feb; 34(8):108765. PubMed ID: 33626345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.
    Chen Y; Li H; Chen D; Jiang X; Wang W; Li D; Shan H
    Dig Dis Sci; 2022 Aug; 67(8):3806-3816. PubMed ID: 34383201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.